Angel Adegbesan

Scribe Therapeutics Inc., a clinical-stage developer of gene therapies for heart diseases, raised $128.7 million in an upsized initial public offering priced at the top of its marketed range.

Scribe Therapeutics Inc., a clinical-stage developer of gene therapies for heart diseases, surged 67% on Friday after raising $128.7 million in an upsized initial public offering.

Apnimed Inc., a late-stage drug developer focused on sleep apnea, is seeking to raise as much as $160 million in a US initial public offering.

(Bloomberg) -- Apnimed Inc., a late-stage drug developer focused on sleep apnea rose 6.3% on Friday after raising $192 million in an upsized US initial public offering.

Latigo Biotherapeutics Inc. is seeking to raise as much as $288 million in an initial public offering, joining a growing list of biotechnology firms considering going public as soon as this quarter.

Wall Street’s appetite for weight-loss drug stocks over the past four years has powered Eli Lilly & Co. to consistently trade above $1,000 per share. Now, some see the pharma giant’s stock as primed for a split.

Latigo Biotherapeutics Inc., a clinical-stage developer of non-opioid pain medicines, raised $345.6 million in an upsized initial public offering, priced at the top of a marketed range.

(Bloomberg) -- Latigo Biotherapeutics Inc., a clinical-stage developer of non-opioid pain medicines, climbed 17% on Friday after raising $345.6 million in an upsized initial public offering, priced at the top of a marketed range.

A record surge in Moderna Inc.’s shares delivered a $5 billion blow to short sellers who had bet that the vaccine maker’s years-long slump would continue.

(Bloomberg) -- A record surge in Moderna Inc.'s shares delivered a $5 billion blow to short sellers who had bet that the vaccine maker's years-long slump would continue.